FBLG Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

FibroBiologics Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerFBLG

Market Cap5.9M

Cash RunwayRunway < 6 months

Next CatalystData Readout

Public Research Snapshot

FibroBiologics Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for CYWC628 in Phase 1/2 Diabetic Foot Ulcer Clinical Trial (Phase 1/2).

Pipeline

Asset	Indication	Modality	Stage	Public Note
CYWC628	Phase 1/2 Diabetic Foot Ulcer Clinical Trial	n/a	Phase 1/2	Public pipeline row
Company Information	chronic diseases	Cell Therapy	n/a	Public pipeline row

Catalyst Preview

Company	Ticker	Catalyst	Timing	Asset	Confidence
		Data Readout	Timing not specified	n/a	Low

Cash Runway Preview

Estimated cash runway: Runway < 6 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
No public trial rows are loaded yet.

Scientific Context

catalyst_type | Data Readout
catalyst_type | Data Readout
catalyst_type | Data Readout
catalyst_type | Data Readout
catalyst_type | Data Readout

Want the full FBLG research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.